News in brief

ABSTRACT

[...]there's no guidance." On 1 May, the US Food and Drug Administration (FDA) granted an 'emergency-use authorization' for clinicians to use the drug, which is administered intravenously, in hospitals for people with severe COVID-19. On 29 April, Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID), said that the latest clinical trial, involving more than 1,000 people, showed that those taking remdesivir recovered in 11 days on average, compared with 15 days for those on a placebo.